Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Growth in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 494,378 shares, an increase of 298.4% from the November 30th total of 124,098 shares. Currently, 80.0% of the company’s stock are short sold. Based on an average daily trading volume, of 3,356,723 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 3,356,723 shares, the short-interest ratio is currently 0.1 days. Currently, 80.0% of the company’s stock are short sold.

Biodexa Pharmaceuticals Stock Down 11.5%

BDRX opened at $2.86 on Thursday. Biodexa Pharmaceuticals has a 12-month low of $2.83 and a 12-month high of $92.00. The firm’s fifty day moving average price is $5.45 and its 200 day moving average price is $6.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.